Accolades and credibility Xeno Diagnostics has a track record of multiple Laboratory Excellence awards from COLA across several years, signaling strong quality and compliance that can help shorten due diligence for potential partner projects and collaborations.

SME scale advantage With a lean team of 2-10 employees, Xeno Diagnostics operates as a focused, agile partner for specialized translational medicine programs, offering customizable in vitro diagnostic services and preclinical study support that can complement larger CROs or in-house teams.

Biotech tech stack Utilizes cloud and web-based tools (Google Ads, AWS, WordPress, Shopify) and web integrations (oEmbed, reCAPTCHA, jQuery Migrate, ZURB Foundation) suggesting capability for digital partnering, client portals, and scalable service delivery and marketing collaboration.

Expansion opportunities Founded in 2007 with a focus on translational medicine and stem cell enumeration assays, there is potential to expand into broader diagnostics services, translational collaborations, or contract research for additional disease models and biomarker development.

Revenue potential Current reported revenue range of 10 to 25 million indicates a mid-market biotech service provider with room to scale collaborations, co-development arrangements, and recurring testing programs with mid-to-large biopharma and academia clients.